*Purpose: ABO-incompatible living kidney transplantation (ABOILKT) has steadily become more widespread. However, the optimal immunosuppressive regimen for ABOILKT remains uncertain. We aimed to determine the outcomes according to dose of rituximab induction.

*Methods: Direct and indirect network meta-analyses using Bayesian models and generation of rankings of rituximab dose via mixed treatment comparison. We searched the following databases for all studies published through to May 15, 2019: Cochrane Central Register, OVID MEDLINE, EMBASE, and PubMed. We reviewed all relevant reviews, registered trials, and relevant conference proceedings to compare clinical outcomes and survival according to dose of rituximab as induction in kidney transplantation

*Results: Twenty-four trias with 4,256 subjects, divided into following four groups: 1) placebo, 2) rituximab 200mg, 3) rituximab 200mg-500mg, 4) rituximab 500mg. Glomerular filtration rates, graft loss, antibody mediated rejection, T-cell mediated rejection, fungal infection (Candida), and patient survival rates did not differ among four groups. However, incidence rate of sepsis 0.728 [95% CrI, 0.572 to 0.926] and CMV infection 0.855 [95% CrI, 0.724 to 0.921] were lower result in using 200mg rituximab group.

*Conclusions: The using of 200mg single dose of rituximab induction in ABOILKR has not only same result about rejection, graft survival and patient’s survival but also low incidence of infection after transplantation

« Back to 2020 American Transplant Congress